164 related articles for article (PubMed ID: 14712062)
1. Evidence of mnt-myc antagonism revealed by mnt gene deletion.
Hurlin PJ; Zhou ZQ; Toyo-Oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
Cell Cycle; 2004 Feb; 3(2):97-9. PubMed ID: 14712062
[TBL] [Abstract][Full Text] [Related]
2. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
Hurlin PJ; Quéva C; Eisenman RN
Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
[TBL] [Abstract][Full Text] [Related]
3. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
4. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
[TBL] [Abstract][Full Text] [Related]
5. Mnt: a novel Max-interacting protein and Myc antagonist.
Hurlin PJ; Qúeva C; Eisenman RN
Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
[TBL] [Abstract][Full Text] [Related]
6. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
[TBL] [Abstract][Full Text] [Related]
7. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
[TBL] [Abstract][Full Text] [Related]
8. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes.
Wahlström T; Belikov S; Arsenian Henriksson M
Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Max-binding protein MNT in human medulloblastomas.
Sommer A; Waha A; Tonn J; Sörensen N; Hurlin PJ; Eisenman RN; Lüscher B; Pietsch T
Int J Cancer; 1999 Sep; 82(6):810-6. PubMed ID: 10446446
[TBL] [Abstract][Full Text] [Related]
10. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J
Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213
[TBL] [Abstract][Full Text] [Related]
12. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.
Hurlin PJ; Zhou ZQ; Toyo-oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
EMBO J; 2003 Sep; 22(18):4584-96. PubMed ID: 12970171
[TBL] [Abstract][Full Text] [Related]
13. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor.
Meroni G; Reymond A; Alcalay M; Borsani G; Tanigami A; Tonlorenzi R; Lo Nigro C; Messali S; Zollo M; Ledbetter DH; Brent R; Ballabio A; Carrozzo R
EMBO J; 1997 May; 16(10):2892-906. PubMed ID: 9184233
[TBL] [Abstract][Full Text] [Related]
14. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
15. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
[TBL] [Abstract][Full Text] [Related]
16. CDC6 interacts with c-Myc to inhibit E-box-dependent transcription by abrogating c-Myc/Max complex.
Takayama M; Taira T; Iguchi-Ariga SM; Ariga H
FEBS Lett; 2000 Jul; 477(1-2):43-8. PubMed ID: 10899308
[TBL] [Abstract][Full Text] [Related]
17. Mnt takes control as key regulator of the myc/max/mxd network.
Wahlström T; Henriksson M
Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941
[TBL] [Abstract][Full Text] [Related]
18. Of Myc and Mnt.
Hooker CW; Hurlin PJ
J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
[TBL] [Abstract][Full Text] [Related]
19. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
20. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
Naderi S; Blomhoff HK
J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
